Recurrence Rates in Patients with HER2+ Breast Cancer Who Achieved a Pathological Complete Response after Neoadjuvant Pertuzumab plus Trastuzumab Followed by Adjuvant Trastuzumab: A Real-World Evidenc

 Article Details
Title: Recurrence Rates in Patients with HER2+ Breast Cancer Who Achieved a Pathological Complete Response after Neoadjuvant Pertuzumab plus Trastuzumab Followed by Adjuvant Trastuzumab: A Real-World Evidence Study
Dateline: 2021-03-01    DisplayDateline   
Byline: O'Shaughnessy J, Robert N, Annavarapu S, Zhou J, Sussell J, Cheng A, Fung A
Publication Title: Breast Cancer Research and Treatment  
CTA Link: https://pubmed.ncbi.nlm.nih.gov/33649981/
CTA Text: Read More
Filter(s):*
This creates the tags that filter the listing page by specific taxonomies that display to the right of the main content and read more link.
 
 

top